Everolimus plus lonafarnib for children with progeria
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether adding everolimus to ongoing lonafarnib improves health and slows complications in people with genetically confirmed progeria. It mainly checks safety and early signs of benefit in Phase I/II.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have genetically confirmed progeria confirmed by testing
- You are showing clinical signs of progeria, as the study team judges
- You are currently taking lonafarnib under the Boston protocol 09-06-0298
- You must be able to travel to Boston for study visits and tests
- You have not had serious (grade 3 or 4) side effects in the last 2 months
- You must not have had a major fracture or major surgery in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This trial tests if everolimus can improve social abilities in people with PTEN germline mutations who have social difficulties. It may help those with PTEN Hamartoma Tumor Syndrome by targeting a specific pathway in the body.
This Phase 2 trial tests whether progerinin is safe and tolerable in adults who have Werner syndrome. You may also be screened for bone thinning/osteoporosis, and you’d need regular visits and pregnancy prevention measures if applicable.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
This trial tests a drug called alpelisib for children and adults with a rare overgrowth condition called PROS that is caused by a PIK3CA gene change. It aims to see if the drug can safely shrink overgrowth and improve symptoms.
Hear when a new Progeria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.